The Next Generation of GLP-1s: Orforglipron, Retatrutide, CagriSema, and Oral Semaglutide

The short version

The current GLP-1 drugs are not the end of the road. Four candidates are furthest along and worth understanding, because they change the two things people care about most: how the drug is taken, and how much weight it removes. Orforglipron is an *oral* small-molecule GLP-1 that could end the injection requirement¹. Retatrutide is a *triple* agonist that produced the largest weight loss yet seen in a mid-stage trial³. CagriSema and high-dose oral semaglutide push efficacy and convenience further within the established framework⁴⁵. This primer sticks to what the published trials actually reported — and flags where a drug is still in testing rather than approved.

Orforglipron: the oral GLP-1 that isn't a peptide

Today's GLP-1s are peptides, which is why most are injected (peptides are poorly absorbed by mouth). Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist — a once-daily pill with no food or water timing restrictions, unlike current oral semaglutide¹. In its phase 2 trial, mean weight change at 36 weeks ranged from about −9.4% to −14.7% across doses, versus −2.3% with placebo². The phase 3 ATTAIN-1 trial then tested it in adults with obesity over 72 weeks: weight change reached −11.2% at the 36 mg dose versus −2.1% with placebo, with 36% of top-dose participants losing at least 15% of body weight¹. As with the whole class, gastrointestinal side effects were the most common, and a minority discontinued because of them¹. The strategic significance is manufacturing and access as much as efficacy: a small molecule is far easier to make at scale than an injectable peptide.

Retatrutide: the triple agonist

Retatrutide targets three receptors at once — GIP, GLP-1, and glucagon — the last of which adds an energy-expenditure lever on top of appetite reduction³. In its phase 2 trial, the results were striking: at 48 weeks, mean weight loss reached −24.2% at the highest (12 mg) dose versus −2.1% with placebo, and every participant on the two highest doses lost at least 5% of body weight³. That is the largest mid-stage weight-loss figure reported for the class to date. The important caveats: this was a phase 2 dose-finding study, not a confirmatory phase 3, and the side-effect profile was again dominated by dose-related gastrointestinal effects³. Retatrutide is investigational and not FDA-approved.

CagriSema: adding amylin to semaglutide

CagriSema pairs semaglutide with cagrilintide, a long-acting analogue of amylin — a second satiety hormone — so it works through two complementary appetite pathways. In the phase 3 REDEFINE 1 trial, adults with overweight or obesity lost a mean of 20.4% of body weight at 68 weeks versus 3.0% with placebo⁴. Gastrointestinal adverse events were common (about 80% of the CagriSema group versus 40% on placebo), consistent with the class⁴. CagriSema represents the "combination" strategy: rather than a single novel molecule, it stacks two mechanisms to push efficacy toward the 20%+ range.

High-dose oral semaglutide: more of a known quantity

Semaglutide already exists as a low-dose oral tablet, but a 50 mg once-daily formulation was tested for weight loss in the phase 3 OASIS 1 trial. Over 68 weeks, participants lost a mean of 15.1% of body weight versus 2.4% with placebo, with 54% reaching at least 15% loss⁵. That brings injection-level efficacy to a daily pill using a molecule clinicians already know well — a meaningful option for people who won't or can't inject, though the oral formulation carries strict dosing conditions (empty stomach, limited water, wait before eating).

How to read all of this as an evidence-minded patient

A few disciplines are worth holding onto:

- **Trial phase matters.** Orforglipron, CagriSema, and oral semaglutide 50 mg have phase 3 data¹⁴⁵; retatrutide's headline number is from phase 2³. Bigger, later trials sometimes temper early figures. - **Cross-trial comparisons are imperfect.** These studies enrolled different populations over different durations, so a −24% in one trial and a −20% in another are not a head-to-head result. - **The side-effect pattern is consistent.** Gastrointestinal effects dominate across every one of these agents¹³⁴, and none of the newer options has erased that. - **Approval and availability lag the headlines.** Being investigational is not the same as being available, and none of these should be sourced from anywhere other than a legitimate prescriber and pharmacy.

For now, the approved tools are the ones our reviews cover — if you're weighing the two current front-line molecules, see semaglutide vs tirzepatide for mothers, and our ranking of GLP-1 providers for women covers who prescribes them well. This article is educational only and not medical advice; drug choice belongs with a clinician who knows your history.